Aclaris Therapeutics (ACRS) Net Margin (2017 - 2025)
Historic Net Margin for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to 464.69%.
- Aclaris Therapeutics' Net Margin fell 2695600.0% to 464.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 922.44%, marking a year-over-year decrease of 7811300.0%. This contributed to the annual value of 705.48% for FY2024, which is 4223300.0% down from last year.
- As of Q3 2025, Aclaris Therapeutics' Net Margin stood at 464.69%, which was down 2695600.0% from 922.34% recorded in Q2 2025.
- Aclaris Therapeutics' Net Margin's 5-year high stood at 10.57% during Q4 2023, with a 5-year trough of 1702.25% in Q2 2023.
- Moreover, its 5-year median value for Net Margin was 987.17% (2021), whereas its average is 871.15%.
- As far as peak fluctuations go, Aclaris Therapeutics' Net Margin crashed by -15871200bps in 2021, and later soared by 13050700bps in 2024.
- Aclaris Therapeutics' Net Margin (Quarter) stood at 1525.18% in 2021, then surged by 75bps to 375.07% in 2022, then skyrocketed by 97bps to 10.57% in 2023, then plummeted by -9917bps to 1059.3% in 2024, then surged by 56bps to 464.69% in 2025.
- Its last three reported values are 464.69% in Q3 2025, 922.34% for Q2 2025, and 1094.02% during Q1 2025.